Statins, inflammation and deep vein thrombosis: A systematic review

Journal of Thrombosis and Thrombolysis

Volumn 33, Issue 4, 2012, Pages 371-382

  Rodriguez, April L ^a   Wojcik, Brandon M ^a   Wrobleski, Shirley K ^a   Myers, Daniel D ^a,b   Wakefield, Thomas W ^a   Diaz, Jose A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Anti coagulation; Biomarker; Deep vein thrombosis; Inflammation; Statins; Venous thromboembolism

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NCX 6560; PRAVASTATIN; PSI 421; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE;

ANTIINFLAMMATORY ACTIVITY; CONTROLLED CLINICAL TRIAL (TOPIC); DATA ANALYSIS; DEEP VEIN THROMBOSIS; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; INFLAMMATION; LUNG EMBOLISM; NONHUMAN; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; VASCULAR FIBROSIS; VEIN WALL; VEIN WALL FIBROSIS; MEDLINE; METABOLISM; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

C-REACTIVE PROTEIN; CYTOKINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYMETHYLGLUTARYL-COA SYNTHASE; MEDLINE; PULMONARY EMBOLISM; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84865145601     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0687-9     Document Type: Review

References (41)

1. Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH (2010) Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med 38(4 Suppl):S502-S509
2. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK et al (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98(4):756-764
3. Hopkins NF, Wolfe JH (1992) ABC of vascular diseases. Deep venous insufficiency and occlusion. BMJ 304(6819):107-110
4. Ackroyd JS, Browse NL (1986) The investigation and surgery of the post-thrombotic syndrome. J Cardiovasc Surg (Torino) 27(1): 5-16
5. Negus D (1970) The post-thrombotic syndrome. Ann R Coll Surg Engl 47(2):92-105
6. Ashrani AA, Heit JA (2009) Incidence and cost burden of postthrombotic syndrome. J Thromb Thrombolysis 28(4):465-476
7. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd (2005) Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 143(10):697-706
8. Linkins LA, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 139(11): 893-900
9. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG et al (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360(18):1851-1861
10. Undas A, Brozek J, Musial J (2002) Anti-inflammatory and antithrombotic effects of statins in the management of coronary artery disease. Clin Lab 48(5-6):287-296
11. Arslan F, Pasterkamp G, de Kleijn DP (2008) Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective. Circ Res 103(4):334-336
12. Nishino M, Hoshida S, Kato H, Egami Y, Shutta R, Yamaguchi H, Tanaka K, Tanouchi J, Hori M, Yamada Y (2008) Preprocedural statin administration can reduce thrombotic reaction after stent implantation. Circ J 72(2):232-237
13. Perez A, Bartholomew JR (2010) Interpreting the JUPITER trial: statins can prevent VTE, but more study is needed. Cleve Clin J Med 77(3):191-194
14. Ali T, Humphries J, Burnand K, Sawyer B, Bursill C, Channon K, Greaves D, Rollins B, Charo IF, Smith A (2006) Monocyte recruitment in venous thrombus resolution. J Vasc Surg 43(3): 601-608
15. Ay C, Jungbauer LV, Sailer T, Tengler T, Koder S, Kaider A, Panzer S, Quehenberger P, Pabinger I, Mannhalter C (2007) High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem 53(7):1235-1243
16. Henke PK, Wakefield TW, Kadell AM, Linn MJ, Varma MR, Sarkar M, Hawley A, Fowlkes JB, Strieter RM (2001) Interleukin-8 administration enhances venous thrombosis resolution in a rat model. J Surg Res 99(1):84-91
17. Meier TR, Myers DD Jr., Wrobleski SK, Zajkowski PJ, Hawley AE, Bedard PW, Ballard NE, Londy FJ, Kaila N, Vlasuk GP et al (2008) Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb Haemost 99(2):343-351
18. Ramacciotti E, Blackburn S, Hawley AE, Vandy F, Ballard-Lipka N, Stabler C, Baker N, Guire KE, Rectenwald JE, Henke PK et al (2011) Evaluation of soluble p-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost 17(4):425-431
19. Roumen-Klappe EM, den Heijer M, van Uum SH, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H (2002) Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 35(4):701-706
20. Roumen-Klappe EM, Janssen MC, Van Rossum J, Holewijn S, Van Bokhoven MM, Kaasjager K, Wollersheim H, Den Heijer M (2009) Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost 7(4):582-587
21. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113(8):636-642
22. van Aken BE, den Heijer M, Bos GM, van Deventer SJ, Reitsma PH (2000) Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 83(4):536-539
23. van Aken BE, Reitsma PH, Rosendaal FR (2002) Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 116(1):173-177
24. Vormittag R, Hsieh K, Kaider A, Minar E, Bialonczyk C, Hirschl M, Mannhalter C, Pabinger I (2006) Interleukin-6 and interleukin-6 promoter polymorphism (-174) G[C in patients with spontaneous venous thromboembolism. Thromb Haemost 95(5): 802-806
25. Vormittag R, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C, Hirschl M, Pabinger I (2005) Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost 93(3):488-493
26. Wakefield TW, Greenfield LJ, Rolfe MW, DeLucia A 3rd, Strieter RM, Abrams GD, Kunkel SL, Esmon CT, Wrobleski SK, Kadell AM et al (1993) Inflammatory and procoagulant mediator interactions in an experimental baboon model of venous thrombosis. Thromb Haemost 69(2):164-172
27. Wakefield TW, Strieter RM, Downing LJ, Kadell AM, Wilke CA, Burdick MD, Wrobleski SK, Phillips ML, Paulson JC, Anderson DC et al (1996) P-selectin and TNF inhibition reduce venous thrombosis inflammation. J Surg Res 64(1):26-31
28. Wojcik BM, Wrobleski SK, Hawley AE, Wakefield TW, Myers DD Jr., Diaz JA (2011) Interleukin-6: a potential target for postthrombotic syndrome. Ann Vasc Surg 25(2):229-239
29. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, Kashanipour A, Minar E, Baghestanian M (2002) Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 22(7):1194-1199
30. Albert MA, Danielson E, Rifai N, Ridker PM (2001) Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286(1):64-70
31. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F (2005) Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 25(6):1231-1236
32. Di Garbo V, Bono M, Di Raimondo D, De Simone R, Raneli G, Avellone G (2000) Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. Eur J Clin Pharmacol 56(4):277-284
33. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M (2010) Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159(6):1294-1303
34. Millar JS, Ky B, Wolfe ML, Pruscino L, Baer A, Rader DJ (2010) Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels. Clin Transl Sci 3(4): 140-146
35. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y, Izumi A, Saito Y, Hamakubo T, Kodama T (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9(4):178-183
36. Doggen CJ, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM (2004) HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2(5):700-701
37. Khemasuwan D, Divietro ML, Tangdhanakanond K, Pomerantz SC, Eiger G (2010) Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 123(1): 60-65
38. Lacut K, Oger E, Le Gal G, Couturaud F, Louis S, Leroyer C, Mottier D (2004) Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based casecontrol study. Fundam Clin Pharmacol 18(4):477-482
39. Momi S, Impagnatiello F, Guzzetta M, Caracchini R, Guglielmini G, Olivieri R, Monopoli A, Gresele P (2007) NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol 570(1-3):115-124
40. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-Teeuwisse AK, Rosendaal FR, Doggen CJ (2009) HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 7(4): 514-520
41. Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A (2001) Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161(11):1405-1410